BofA analyst Geoff Meacham lowered the firm’s price target on Vertex Pharmaceuticals to $541 from $550 and keeps a Buy rating on the shares. The cystic fibrosis, CF, franchise continues to growth and the firm notes near-term focus is on the anticipated launch of vanzacaftor triple in 2025, the analyst tells investors. Key opinion leaders have expressed enthusiasm about the approval and anticipate significant switching from other agents, the firm adds. The firm is encouraged by the strong underlying base business provided by the CF franchise and see several opportunities to expand the pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals reinstated with a Market Perform at Raymond James
- Vertex Pharmaceuticals price target raised to $437 from $425 at RBC Capital
- CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts
- Vertex Pharmaceuticals price target raised to $474 from $462 at Morgan Stanley
- Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher